TY - JOUR
T1 - Autoimmune encephalitis in Israeli children – A retrospective nationwide study
AU - Sachs, Nimrod
AU - Zohar-Dayan, Efrat
AU - Ben Zeev, Bruria
AU - Gilboa, Tal
AU - Kurd, Mohammad
AU - Latzer, Itay Tokatly
AU - Meirson, Hadas
AU - Krause, Irit
AU - Dizitzer, Yotam
AU - Cohen, Esther Ganelin
N1 - Publisher Copyright:
© 2024 European Paediatric Neurology Society
PY - 2024/5
Y1 - 2024/5
N2 - Immune-mediated or autoimmune encephalitis (AE) is a relatively new, rare and elusive form of encephalitis in children. We retrospectively collected seropositive children (0–18 years old) with well characterized antibodies through 3 reference laboratories in Israel. Clinical symptoms, MRI and EEG findings and treatment courses were described. A total of 16 patients were included in the study, with 10 females. Anti NMDA encephalitis was most common followed by anti HU and anti mGLuR1. Psychiatric symptoms, abnormal movements, seizures and behavioral changes were the most common presentation. Pathological MRI and EEG findings were described in 37% and 56% of children, respectively. Treatment with corticosteroids, Intravenous immunoglobulins (IVIG) was first line in most children. Following inadequate response children were treated with plasmapheresis and/or rituximab. Two patients relapsed following both first and second line protocols. In terms of long term prognosis, 9 children (56%) had one or more residual behavioral, psychiatric or neurologic findings. Three children required hospitalization for rehabilitation. AE remains a rare diagnosis with variable presenting symptoms, requiring a high index of suspicion. Consensus recommended treatment is generally effective in the pediatric population. Female gender was associated with a higher chance of severe disease. Larger cohorts would be needed to identify prognostic factors in the pediatric population.
AB - Immune-mediated or autoimmune encephalitis (AE) is a relatively new, rare and elusive form of encephalitis in children. We retrospectively collected seropositive children (0–18 years old) with well characterized antibodies through 3 reference laboratories in Israel. Clinical symptoms, MRI and EEG findings and treatment courses were described. A total of 16 patients were included in the study, with 10 females. Anti NMDA encephalitis was most common followed by anti HU and anti mGLuR1. Psychiatric symptoms, abnormal movements, seizures and behavioral changes were the most common presentation. Pathological MRI and EEG findings were described in 37% and 56% of children, respectively. Treatment with corticosteroids, Intravenous immunoglobulins (IVIG) was first line in most children. Following inadequate response children were treated with plasmapheresis and/or rituximab. Two patients relapsed following both first and second line protocols. In terms of long term prognosis, 9 children (56%) had one or more residual behavioral, psychiatric or neurologic findings. Three children required hospitalization for rehabilitation. AE remains a rare diagnosis with variable presenting symptoms, requiring a high index of suspicion. Consensus recommended treatment is generally effective in the pediatric population. Female gender was associated with a higher chance of severe disease. Larger cohorts would be needed to identify prognostic factors in the pediatric population.
UR - http://www.scopus.com/inward/record.url?scp=85188832466&partnerID=8YFLogxK
U2 - 10.1016/j.ejpn.2024.03.001
DO - 10.1016/j.ejpn.2024.03.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38518418
AN - SCOPUS:85188832466
SN - 1090-3798
VL - 50
SP - 1
EP - 5
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
ER -